Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

UNC Football's Trip to Ireland 'Much More Than a Game'
UNC Football kicks off its season in Dublin, Ireland, playing Texas Christian University on Aug. 29 in the Aer Lingus College Football Classic. But the...
Wed Aug 19, 2026

‘Witness’ Carolina’s role in the Revolutionary War
To commemorate America’s 250th birthday, Wilson Library is hosting a new exhibition. “Witnesses to the Revolution: North Carolina and the War for Independence” explores how...
Wed Aug 19, 2026

UNC students take first-day sips at the Old Well
It’s the first day of classes at Carolina, and as Tar Heels know, that means it’s also time to drink from the Old Well for...
Mon Aug 17, 2026

Nonprofit at UNC pairs those with chronic illnesses with a service dog
UNC’s chapter of Lux’s Purpose was founded this year. Service dogs cost as much as $50,000-$70,000, and there is not a single insurance plan that...
Sun Aug 16, 2026